Gene expression linked to survival differs by kidney cancer subtype
Renal cell carcinoma (RCC) is the most common form of kidney cancer, accounting for about 90% of kidney cancers. It develops when abnormal cells in the kidney's small tubules begin to grow uncontrollably. RCC has several subtypes that differ in their origin, molecular characteristics and genetic makeup.
A recent study conducted by researchers at Tokyo University of Science and Nippon Medical School has revealed that the expression of a specific gene, CTDNEP1, is linked to differences in survival outcomes among patients with renal cell carcinoma (RCC) depending on the subtype of the cancer. RCC is the most common form of kidney cancer, accounting for about 90% of all cases, and it is classified into several subtypes, the most common being clear cell RCC (ccRCC) and papillary RCC (pRCC).
The study, led by Professor Tadayoshi Hayata and first author Mayuka Nii, examined genetic data from 512 patients with ccRCC and 283 with pRCC and found that patients with higher levels of CTDNEP1 expression had significantly poorer survival outcomes, particularly in cases of stage III disease. The researchers suggest that CTDNEP1 may serve as a candidate prognostic biomarker in RCC, but further experimental and clinical validation is needed to confirm its direct involvement in cancer progression.
The study also highlights that the clinical meaning of CTDNEP1 expression may vary depending on the cancer type and subtype, with different biological pathways being associated with the gene in ccRCC and pRCC.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
